Depomed, Inc.

Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Founded in 1995, Depomed has successfully executed on strategy of acquiring, integrating and growing differentiated therapeutic products and building each into a strong market presence. The result is a broad portfolio of pain and neurology specialty pharmaceuticals currently comprised of five FDA-approved products. These include the company’s flagship asset, the NUCYNTA® franchise which includes NUCYNTA® ER for the extended management of pain, including neuropathic pain associated with diabetic peripheral neuropathy.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

Asset Management Operations And Maintenance Forum for Oil Gas Refinery Chemicals And Petrochemicals

Conference

26th International Congress of Chemical and Process Engineering CHISA 2022.

Conference

22nd Tetrahedron Symposium Catalysis for a Sustainable World

Conference

Exploring Fluxes, Forms and Origins of Deep Carbon in Earth and Other Terrestrial Planets

Conference

Plastics Recycling Technology

Conference

CHEMICALS AND CHEMICAL WASTE HANDLING STORAGE AND DISPOSAL

Webinar

Related News

OAK RIDGE NATIONAL LABORATORY RESEARCHERS FIND AMBIGUOUS LIQUID-LIQUID INTERFACE SEPARATION CHEMISTRY

Phys | August 06, 2020

Real-time measurements captured by researchers at the Department of Energy's Oak Ridge National Laboratory provide missing insight into chemical separations to recover cobalt, a critical raw material used to make batteries and magnets for modern technologies. Results published in ACS Applied Materials and Interfaces, track the dynamics of molecules designed to grab cobalt from solutions containing a mixture of similar species. "Understanding the molecular events that make it possible to...

CHEMICAL MANAGEMENT

AEMETIS ACQUIRES $2 MILLION PROPERTY NEAR KEYES ETHANOL PLANT FOR CARBON ZERO PROJECTS

Aemetis, Inc. | April 05, 2022

Aemetis, Inc. a renewable fuels company focused on negative carbon intensity products announced the acquisition of an 8.5-acre property on Faith Home Road for $2 million, located approximately 1/4 mile from the Aemetis Keyes renewable ethanol plant. The corner property is a strategic location for operations supporting the company’s Carbon Zero projects, including dairy renewable natural gas and carbon capture and sequestration. Sited adjacent to the existing Aemetis biogas p...

CHEMICAL INDUSTRY: TRAPPING OF ACETYLENE CONTAMINANTS

Sciencedaily | August 31, 2020

Ethylene is the most important chemical precursor for ethanol and polyethylene and is mainly produced by steam cracking. Although the ethylene fraction is usually very pure (more than 99%), remaining traces of acetylene contaminants can destroy the catalysts used in downstream processes. As ethylene and acetylene are very similar and only differ in the amount of hydrogen atoms -- ethylene has four hydrogen atoms bound to two carbon atoms, acetylene has two -- the separation of both gases is elab...

CHEMICAL TECHNOLOGY

908 DEVICES INTRODUCES A NEW AEROSOL MODULE FOR THE MX908 HANDHELD

Aerosol, Handheld | May 12, 2021

908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced updates to the MX908 handheld mass spec device, including a first-of-its-kind aerosol module to detect and identify aerosolized chemical threats, additional targets allowing responders to recognize additional priority drug substances, and activation of a Bl device. These new features fill in gaps in responders' workflows and speed chemical detection at the po...